PRIMMA real-world outcomes: Risankizumab in moderate-to-severe PsO

Results from the multicenter, prospective, non-interventional PRIMMA study (NCT04780516), evaluating risankizumab in 136 adults with moderate-to-severe psoriasis (PsO), were published in Dermatology and Therapy by Snast et al. The primary endpoint was Dermatology Life Quality Index (DLQI) score at Week 52. Secondary outcomes included the proportion of patients achieving a Static Physician’s Global Assessment of PsO score of 0/1 (sPGA 0/1), a Pruritus Numeric Rating Scale (PNRS) score of 0/1, and a decrease of ≥4 points in PNRS from baseline. 

Key data: At Week 52, 58% of patients had a DLQI score of 0/1 compared with 5.1% at baseline (p < 0.001, n = 78). A PNRS score of 0–3 was achieved in 81% of patients compared with 21% at baseline (p < 0.001), with a decrease of ≥4 points from baseline observed in 57% of patients (n = 75). An sPGA score of 0/1 was observed in 77% of patients at Week 52 vs 0% at baseline (p < 0.001; n = 86). Adverse events (AEs) occurred in 28% of patients, 92.2% of which were mild to moderate. Serious AEs (SAEs) occurred in 2.2% of patients. Significant improvements were observed from baseline to Week 52 in median Psoriasis Symptoms Scale (PSS; p < 0.001), Work Productivity and Activity Impairment (WPAI; p = 0.045), and Medical Outcomes Study Sleep Scale (MOS-SS; all p < 0.047). 

Key learning: In real-world practice, risankizumab produced substantial, durable improvements in quality of life (QoL), pruritus, sleep, and work/activity outcomes in moderate-to-severe PsO.